SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum

SciSparc Subsidiary NeuroThera Labs Gets Conditional Approval for CliniQuantum Acquisition

SciSparc Ltd. announced that its subsidiary, NeuroThera Labs Inc., received conditional regulatory approval from the TSX Venture Exchange for the acquisition of approximately 54% interest in CliniQuantum Ltd. This transaction, previously disclosed in March 2026, involves NeuroThera acquiring 56,375 ordinary shares of CliniQuantum for the issuance of 56,600,000 common shares of NeuroThera, valued at approximately $9,459,954.20. CliniQuantum is an Israeli technology company developing a platform using quantum simulation for clinical trial data analysis to improve precision and identify patient subpopulations. The acquisition is subject to further conditions, including an Israeli tax ruling and final TSX acceptance, with an extended completion date of June 1, 2026.

• NeuroThera Labs, a subsidiary of SciSparc, secured conditional regulatory approval from the TSX Venture Exchange for its acquisition of a 54% stake in CliniQuantum Ltd. This marks a significant step towards finalizing the transaction, which aims to integrate CliniQuantum's quantum simulation platform into NeuroThera's operations.
• The acquisition involves NeuroThera issuing 56,600,000 common shares to CliniQuantum's selling shareholders, valued at approximately $9,459,954.20 based on NeuroThera's 20-day volume-weighted average trading price on the TSX. This consideration is for 56,375 ordinary shares of CliniQuantum, representing a controlling interest.
• CliniQuantum is an Israeli technology company specializing in a platform that applies quantum simulation and Monte Carlo methods to clinical trial data. Its technology aims to enhance the precision of clinical trial outcomes by identifying specific patient subpopulations that respond effectively to investigational therapies, which is a key strategic asset for NeuroThera.
• The transaction's completion is contingent upon several conditions, including obtaining an Israeli tax ruling and final acceptance from the TSX. The outside date for completing the acquisition has been extended from April 30, 2026, to June 1, 2026, to allow sufficient time for these remaining conditions to be met.

Addressing Unmet Needs in CNS Through Quantum Analytics Acquisition

Recent research highlights significant gaps in CNS disorder treatment, with several critical patient populations facing limited therapeutic options. The literature reveals urgent needs spanning brain tumors, neurodegenerative diseases, and drug delivery challenges that continue to drive clinical and research priorities.

• Brain metastases patients face devastating outcomes with 84% overall mortality rates and poor survival trajectories (47% at 6 months, declining to 2% at 5 years), creating urgent demand for CNS-penetrant compounds targeting genetic mutations enriched in brain metastases

• Glioblastoma remains virtually untreatable despite decades of research, with standard-of-care unchanged for 20 years and average survival of only 14-15 months, while immune checkpoint inhibitors have failed to replicate their success from other cancers

• Drug delivery across the blood-brain barrier represents a fundamental bottleneck preventing up to 98% of potential neuropharmaceuticals from reaching the CNS, severely limiting therapeutic development across all neurological conditions

• Neurodegenerative disease populations face an unprecedented burden with Alzheimer's disease alone expected to impact over 115 million people by 2050 at a cost exceeding $1 trillion annually to the U.S. economy, yet disease-modifying therapies remain elusive

• Recurrent brain tumor patients encounter severely limited options as additional surgical resections pose life-threatening risks, patients may be ineligible for further radiation, and tumors often develop chemotherapy resistance

• Comprehensive management strategies are needed for high-risk populations including patients with gastrointestinal-originated brain metastases and those requiring prevention approaches, as current surveillance and prophylaxis methods remain inadequate

Overcoming CNS Treatment Hurdles with Quantum Clinical Trial Analysis

The most significant barrier to effective CNS treatment remains the blood-brain barrier (BBB), which fundamentally restricts therapeutic access to cerebral parenchyma. This tightly regulated, semipermeable barrier prevents molecules larger than 500 kDa from crossing into brain tissue, severely limiting drug bioavailability in the CNS. Only molecules with molecular weight below 400 Da and sufficient lipid solubility can effectively traverse the BBB, creating a critical bottleneck for therapeutic development. The BBB's dynamic and adaptable nature further complicates drug delivery strategies, as its protective mechanisms that guard against xenobiotics simultaneously impede beneficial therapeutics from reaching optimal concentrations in brain tissue.

Current conventional therapeutics face multiple formulation and delivery challenges that compromise their clinical efficacy. These limitations include poor drug solubility, restricted blood-brain barrier penetration, extensive first-pass metabolism, short elimination half-lives, and low brain bioavailability coupled with systemic adverse effects. Even when therapeutics demonstrate promise in preclinical settings, they frequently remain critically below optimal therapeutic efficacy levels in clinical applications. The complexity is exemplified in multiple sclerosis treatment, where despite decades of development and several approved therapies, complete remission remains elusive.

The fundamental characteristics of neurodegenerative diseases present additional treatment hurdles beyond drug delivery. These conditions typically have unknown etiology and unfavorable prognoses, with insidious onset and progressive development that complicates early diagnosis, particularly in elderly populations where initial clinical manifestations are often atypical. Most neurodegenerative diseases are characterized by protein aggregate hallmark lesions, yet despite an enormous market demand, no disease-modifying drugs currently exist. The research landscape is further constrained by inadequate funding, with brain disorders costing Europe nearly 400 billion euros annually while brain research receives only 1% of that amount in funding allocation.

Quantum Analytics: A New Frontier for Clinical Trials

The pharmaceutical industry is at a critical juncture, constantly seeking innovative ways to overcome the formidable challenges of drug development, including escalating costs and high failure rates in clinical trials. SciSparc's subsidiary, NeuroThera Labs Inc., has made a notable move by acquiring a majority stake in CliniQuantum Ltd., an Israeli technology company focused on leveraging quantum simulation for clinical trial data analysis.

This strategic investment signals a clear intent to embrace precision medicine and advanced analytics. CliniQuantum's platform aims to improve the identification of specific patient subpopulations, a crucial step towards developing more targeted and effective therapies. The promise here is substantial:

• Enhanced R&D Efficiency: By better stratifying patients, trials could become smaller, faster, and more cost-effective, potentially reducing the significant financial and time investments currently required.

• Improved Efficacy and Safety: More precise patient selection could lead to higher success rates for investigational drugs, minimizing exposure to ineffective treatments and improving overall patient outcomes.

• Competitive Edge: Early adoption of quantum simulation principles in drug development could position SciSparc/NeuroThera Labs as a leader in a rapidly evolving technological landscape.

However, this pioneering approach is not without its inherent risks. The novelty of quantum simulation in this context means that its real-world efficacy and scalability in large-scale clinical settings are yet to be fully proven. Furthermore, regulatory bodies will need to establish frameworks for validating and accepting such advanced analytical methods, which could introduce delays. The substantial financial commitment for a nascent technology, coupled with the historical context of high-profile clinical trial failures in the industry—even for seemingly promising interventions like transcranial laser therapy in acute stroke—underscores the inherent volatility and risk associated with pharmaceutical R&D. Successfully integrating CliniQuantum's technology and demonstrating its tangible benefits will be paramount for SciSparc/NeuroThera Labs to realize the full potential of this ambitious acquisition.